Home > Newsletters > RxTrials Institute Drug Pipeline Alert > Cytokinetics Ready to Move Forward With Trial for Heart Drug
RxTrials Institute Drug Pipeline Alert
Dec. 24, 2008 | Vol. 6 No. 52
Cytokinetics Ready to Move Forward With Trial for Heart Drug
Cytokinetics received encouraging data from a Phase IIa clinical trial evaluating the safety of CK-1827452 in patients with ischemic cardiomyopathy and angina.
The double-blind, randomized, placebo-controlled Phase IIa clinical trial was designed to evaluate both intravenous and oral formulations of the drug. The primary objective was to assess the effect of the drug on the patients’ symptom-limited treadmill exercise tolerance.
Cytokinetics said it was pleased with the results and, based on the data and results from other trials with the drug, the company will begin a Phase IIb program in mid-2009.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.